DermTech (DMTK) CEO On Dermatology Genomics

<p>DermTech (DMTK) is a dermatology genomics company that develops and markets novel non-invasive genomics tests. John Dobak, CEO of DermTech, discusses DMTK, as it is part of the NASDAQ Biotechnology Index (NBI). He talks about how DMTK has reached an agreement with BioIQ for its melanoma test to be included in health programs. He then goes over the outlook for DMTK. Tune in to find out more.</p>